Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Davis Polk Advises Mereo BioPharma Group plc on Its Combination with OncoMed Pharmaceuticals, Inc.
Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction,…
DexCom, Inc. $850 Million Convertible Notes Offering
Davis Polk advised the representatives of several initial purchasers in connection with a Rule 144A offering by DexCom, Inc…
Taiwan Liposome Company, Ltd. Initial Public Offering
Davis Polk advised the book-running manager and representative of the underwriters in connection with the initial public…
Orchard Therapeutics plc Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the…
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from…
Innovent Biologics, Inc. HK$3.15 Billion (US$403.1 Million) Initial Public Offering
Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong…
Gamida Cell Ltd. $50 Million Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering…
Davis Polk Advises Laboratorios Farmacéuticos Rovi, S.A. on Its €80 Million Follow-On Offering
Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of…
Aetna receives DOJ approval of $77 billion acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed…
Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed…